3652 results for «320»
3652 results
TAVI in a patient with heavily calcified valve anatomy - LIVE case
18 Feb 2023 – From PCR Tokyo Valves 2023
An 80-year-old male with chronic kidney disease and interstitial pneumonia treated under steroids presented a symptomatic severe aortic stenosis with massive calcifications on the valves and only on the valves (not the LVOT).
Watch the operators implant a Sapien 3 23 mm (-1cc) with a predilatation (Balloon...
Future devices and techniques
19 Feb 2023 – From PCR Tokyo Valves 2023
In this session, find out more about TMVR device options and trial updates, a case of severe mitral regurgitation treated with TMVR, ongoing trials and future innovations regarding transcatheter tricuspid valve repair and replacement, and much more!
My worst nightmare in TAVI
Listen to our experts share their most nightmarish TAVI cases and follow the debate around their treatments. For instance, would you make the same choices when faced with a 76-year-old female patient diagnosed as severe AS, transferred for SAVR/TAVI, who got a new Abif and cardiogenic...
PCR Tokyo Valves 2023 Closing Ceremony
19 Feb 2023 – From PCR Tokyo Valves 2023
This closing ceremony of the 2023 edition of the PCR Tokyo Valves is the occasion to unveil the results of the best abstract and best case competitions and to congratulate the finalists. It is also the moment to take stock of this excellent edition, to thank...
TAVI in small annulus and coronary artery disease - Session with LIVE case
19 Feb 2023 – From PCR Tokyo Valves 2023
Watch the complex case of an 84-year-old woman with hypertension, type 2 diabetes and coronary artery disease who presented with worsening NYHA class II-III exertional dyspnoea, but no angina, and find out how she was treated LIVE.
The optimal first valve choice for all patients with aortic stenosis
18 Feb 2023 – From PCR Tokyo Valves 2023
How have advances in TAVI impacted the lifetime journey of patients with aortic stenosis? Join this panel of experts as they discuss the importance of optimizing the first procedure and the key issues regarding treatment options in patients with bioprosthetic valve deterioration of transcatheter heart valve.
How to optimise the lifetime management of TAVI patients with long-life expectancy?
18 Feb 2023 – From PCR Tokyo Valves 2023
This session addresses three essential elements of a successful TAVI procedure: the impact of valve design on long-term durability, how to mitigate the risk of paravalvular leakage, and the importance of the possibility for coronary access after TAVI.
Remaining unmet needs and strategies in TAVI
19 Feb 2023 – From PCR Tokyo Valves 2023
This session focuses on valve design and durability performance in TAVI for patients with aortic stenosis, and the way it impacts future patient outcomes.
Data from benchmark registry demonstrate improved TAVR efficiency with preserved patient safety
17 May 2023
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
EuroPCR 2023 – The interventional cardiovascular community is gathering in Paris to learn, share, and shape the future of patient care worldwide
15 May 2023
EuroPCR, the annual world-leading Course in interventional cardiovascular medicine, has been taking place for over 30 years. It is tailored for all those dedicated to the sharing of knowledge and skills, and improvement of patient care worldwide: interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied...
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial
09 Apr 2024
Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)
Author
Author
